The product is an analog of PTHrP (parathyroid hormone-related protein), a synthetic peptide that is related to hPTHrP and has demonstrated in testing the potential to widen the anabolic window for bone therapeutics, stimulating bone formation with a limited effect on bone resorption and mineral mobilization. This could enable improved convenience over currently available anabolic therapies, resulting in greater compliance and, ultimately, greater benefit.
>99.5% by SDS-Page and HPLC analysis
<0.001 EU per 1 μg of the peptide by the LAL method
Lyophilized peptide should be stored at < -20°C, though stable at room temperature for 3 weeks. Reconstituted peptide solution can be stored at 2-8 °C for 1 week. Aliquots of reconstituted samples are stable at < -20°C for 3 months.
Investigated for use/treatment in postmenopausal osteoporosis to reduce vertebral and/or non-vertebral fractures.
Examples of Clinical Use:
The product, a proprietary analog of human parathyroid hormone-related protein (hPTHrP), is currently undergoing clinical trials by the company for the treatment of osteoporosis in postmenopausal women. PTHrP is a critical peptide for promoting new bone formation, with a distinct role from parathyroid hormone, or PTH, which primarily regulates calcium homeostasis and bone resorption. Clinical studies show increased bone mineral density (BMD) and levels of bone formation markers in a dose-response relationship.
Mechanism of action:
In target cells, abaloparatide acts as an agonist on PTH type 1 receptor (PTH1R) and activates both G protein–mediated cAMP signaling and β-arrestin-mediated ERK-1/2 signaling pathways with similar potency [A19105]. Abaloparatide binds to RG conformation of PTH1R with greater selectivity that results in more transient cell signalling responses.
The parathyroid hormone-related peptide (PTHrP) was discovered in the late 1980s. This peptide shares homology with parathyroid hormone (PTH) in its amino terminus and is secreted by numerous tissues throughout the body. Genetics research shows that the PTHrP gene locus is situated on chromosome 12, specifically 12p11.2-p12.1.
The protein structure of PTHrP is distinctive and complex. It comprises three main regions: the N-terminal, the central, and the C-terminal domains. The N-terminal domain, which shares similarity with PTH, exhibits the majority of the peptide's biological activity, whereas the other two domains play crucial roles in executing multiple effects in target cells.
PTHrP Peptide Function
The PTHrP peptide performs manifold functions, primarily as a hormone and growth factor. It participates in the regulation of epithelial-mesenchymal interactions, cellular proliferation, differentiation, and apoptosis. In the physiological setting, the peptide's most well-defined role is in endochondral bone development—facilitating chondrocyte proliferation and differentiation.
PTHrP Peptide-Related Signaling Pathways
The PTHrP peptide communicates with target cells via numerous signaling pathways, the most significant being the PTH/PTHrP receptor (PTH1R)-mediated cyclic adenosine monophosphate (cAMP) pathway. When PTHrP binds to PTH1R, it initiates the formation of cAMP and consequent activation of protein kinase A. This pathway is vital for intracellular regulatory functions, such as cell survival and division. Another crucial PTHrP signaling pathway is the calcium-related pathway, which the peptide monitors and effectively regulates through maintaining a dynamic equilibrium of calcium concentrations.
PTHrP Peptide-Related Diseases
Anomalies in PTHrP expression and its signaling pathways have been linked to several diseases. Over-production of PTHrP is responsible for hypercalcemia of malignancy, a condition marked by dangerously high levels of bodily calcium. Additionally, the peptide's over-expression in breast and prostate cancer often correlates with increased bone metastases, leading to significant oncological complications.
Interestingly, Interferon Beta-1a, a drug famously used for treating multiple sclerosis, is being explored for its potential therapeutic effects on these PTHrP-related conditions. It has been observed to down-regulate PTHrP expression in breast cancer cells, thus potentially reducing the risk of bone metastases and controlling hypercalcemia.
Application of PTHrP Peptide in Medicine
The biomedical understanding of PTHrP peptide, its functions, and signaling pathways has armed scientists and physicians with potential therapeutic tools. Its capacity to regulate calcium levels has particularly significant therapeutic implications, primarily in managing disorders related to calcium imbalances.
List of Drug Candidates Related to PTHrP Peptide
In the quest to target diseases implicated with PTHrP, several drug candidates are being explored. These include:
Abaloparatide: This synthetic analog of PTHrP is used for treating osteoporosis in postmenopausal women, where it fosters bone growth and reduces the risk of fractures.
PTHrP [1-34]: It is studied for its capability to stimulate bone formation, highlighting its potential use in osteoporosis therapy.
Anti-PTHrP Antibodies: These are being studied for their potential in blocking PTHrP's tumor-advancing actions in various cancers.
The exploration and development of PTHrP peptide-related drugs are increasingly contributing to the medical community's strategic armory against various diseases. As our understanding of PTHrP's intricate biology deepens, it is with great anticipation that we envision the emergence of novel, peptide-modulated therapies with the capacity to alleviate significant human disease.
For research use only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products
without prior written approval from Creative BioMart.
For more information on how our products could help advance your project, please contact us.